Albumin Administration in Chronic Liver Disease

Established Indications

The American Association for the Study of Liver Diseases recommends administering albumin when removing >5L of ascitic fluid to prevent paracentesis-induced circulatory dysfunction, with moderate certainty of evidence 1, 2, 3
Administer 1.5 g/kg at diagnosis and 1.0 g/kg on day 3 for spontaneous bacterial peritonitis, which is a strong recommendation with moderate certainty of evidence 4, 5
Albumin reduces mortality and prevents hepatorenal syndrome in spontaneous bacterial peritonitis patients, with moderate certainty of evidence 2, 3, 5
Use 5% albumin over normal saline in cirrhotic patients with sepsis-induced hypotension, with moderate certainty of evidence 2, 3
A 2024 RCT demonstrated higher 1-week survival with albumin (43.5% vs 38.3%, p=0.03) in sepsis-induced hypotension patients 2, 3

Consider albumin 1.5 g/kg on day 1 followed by 1.0 g/kg on day 3, combined with lactulose, for acute hepatic encephalopathy, with low to very low certainty of evidence 5
Evidence shows 75% complete resolution with albumin-lactulose versus 53% with lactulose alone (p=0.03) in acute hepatic encephalopathy patients 5

Do not use albumin as first-line volume replacement in critically ill patients with cirrhosis, with moderate certainty of evidence 1
Balanced crystalloids (lactated Ringer's) are preferred for initial resuscitation, with moderate certainty of evidence 2, 3, 6
Monitor closely for volume overload, especially in patients with increased capillary permeability, with moderate certainty of evidence 2, 3, 7, 5
Immediately discontinue albumin if pulmonary edema develops, with moderate certainty of evidence 7

Identify the specific indication, such as large-volume paracentesis, spontaneous bacterial peritonitis, hepatorenal syndrome, or sepsis-induced hypotension, and administer albumin accordingly, with moderate certainty of evidence 1, 2, 3, 4, 6
Assess contraindications, such as cardiac and pulmonary function, before administration, with moderate certainty of evidence 5
Monitor during and after administration, using echocardiography to guide fluid management and watching for respiratory distress or declining oxygen saturation, with moderate certainty of evidence 2, 3, 6, 7

The International Collaboration for Transfusion Medicine Guidelines found no improvement in patient-important outcomes when albumin was used for general volume replacement in critically ill cirrhotic patients 8, 9
A 2021 meta-analysis of two small RCTs showed albumin reduced hepatic encephalopathy (RR 0.60, 95% CI 0.38-0.95) and mortality (RR 0.54, 95% CI 0.33-0.90) 8
The ATTIRE trial found no improvement in the composite endpoint of new infections, kidney dysfunction, or death (adjusted OR 0.91, 95% CI 0.44-1.86) with albumin administration 8, 10
The American Thoracic Society recommends against administering albumin for hypoalbuminemia correction alone in decompensated cirrhosis (adjusted OR 0.98, 95% CI 0.71-1.33 for benefit) 8, 9
The guideline panel explicitly abstained from making a recommendation for albumin use in hepatic encephalopathy due to uncertainty 9